Need help finding what you are looking for?
Contact Us
PUBLISHER: QYResearch | PRODUCT CODE: 1867557
PUBLISHER: QYResearch | PRODUCT CODE: 1867557
Human Microbiome - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
PUBLISHED:
PAGES: 121 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global market for Human Microbiome was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.
The Human Microbiome refers to the collective microorganisms and their genetic material residing in various parts of the human body, such as the gut, skin, mouth, respiratory tract, and reproductive system. These microbes form a symbiotic relationship with the human host, playing critical roles in immune modulation, nutrient absorption, metabolic regulation, and disease prevention. With the advancement of high-throughput sequencing, synthetic biology, and artificial intelligence, the commercialization of the microbiome is shifting from basic research toward precision medicine, immunotherapy, probiotics, functional foods, and personalized nutrition. The global human microbiome industry is now entering an accelerated application phase, becoming a model for cross-border integration across healthcare, biotechnology, and nutrition sectors, and attracting major pharmaceutical and biotech companies, as well as emerging startups.
The human microbiome sector has gained momentum due to rising demand for precision medicine, chronic disease management, and alternatives to antibiotics. Increasing evidence from Phase III clinical trials supports the role of gut microbiota in conditions such as cancer, neurological disorders, and autoimmune diseases, accelerating product development in therapeutics, diagnostics, and nutritional interventions. The U.S. and EU have included microbiome initiatives in their national-level precision medicine strategies, and investor interest continues to surge. The global market for microbiome therapeutics is projected to surpass $10 billion by 2030.
Despite the promising outlook, the industry faces significant hurdles. These include individual microbiome variability leading to inconsistent treatment efficacy, lack of standardized clinical validation pathways, and regulatory uncertainty. Technological challenges around scalable manufacturing, storage, activity control, and genomic safety further complicate commercialization. Additionally, public acceptance, ethical concerns, and low physician familiarity with microbiome-based therapies present barriers to market expansion.
Downstream, pharmaceutical, nutritional, and diagnostic companies are accelerating commercialization of microbiome-related products. There is growing demand for gut microbiome therapeutics, fecal microbiota transplantation (FMT), probiotics, and next-generation probiotics (NGPs), particularly in cancer support therapy, autism management, and inflammatory bowel disease. Rising consumer awareness of microbiome balance is also fueling demand in functional food and personalized nutrition, turning the sector into a hotbed for venture capital and strategic investment.
This report aims to provide a comprehensive presentation of the global market for Human Microbiome, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Human Microbiome by region & country, by Type, and by Application.
The Human Microbiome market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome.
Market Segmentation
By Company
- Vedanta
- Seres Therapeutics
- Second Genome
- Rebiotix
- ActoGeniX
- Enterome BioScience
- AvidBiotics
- 4D Pharma Research Ltd
- Enterologics
- Metabogen
- Metabiomics
- Ritter Pharmaceuticals
- Osel
- Symberix
- Miomics
- Symbiotix Biotherapies
- MicroBiome Therapeutics LLC
Segment by Type
- Gastrointestinal Tract Human Micobiome
- Urogenital Tract Human Micobiome
- Others
Segment by Application
- Treatment
- Diagnosis
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Microbiome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Human Microbiome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Human Microbiome in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Human Microbiome Product Introduction
- 1.2 Global Human Microbiome Market Size Forecast (2020-2031)
- 1.3 Human Microbiome Market Trends & Drivers
- 1.3.1 Human Microbiome Industry Trends
- 1.3.2 Human Microbiome Market Drivers & Opportunity
- 1.3.3 Human Microbiome Market Challenges
- 1.3.4 Human Microbiome Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Human Microbiome Players Revenue Ranking (2024)
- 2.2 Global Human Microbiome Revenue by Company (2020-2025)
- 2.3 Key Companies Human Microbiome Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Human Microbiome Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Human Microbiome
- 2.6 Human Microbiome Market Competitive Analysis
- 2.6.1 Human Microbiome Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Human Microbiome Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Microbiome as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Gastrointestinal Tract Human Micobiome
- 3.1.2 Urogenital Tract Human Micobiome
- 3.1.3 Others
- 3.2 Global Human Microbiome Sales Value by Type
- 3.2.1 Global Human Microbiome Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Human Microbiome Sales Value, by Type (2020-2031)
- 3.2.3 Global Human Microbiome Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Treatment
- 4.1.2 Diagnosis
- 4.2 Global Human Microbiome Sales Value by Application
- 4.2.1 Global Human Microbiome Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Human Microbiome Sales Value, by Application (2020-2031)
- 4.2.3 Global Human Microbiome Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Human Microbiome Sales Value by Region
- 5.1.1 Global Human Microbiome Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Human Microbiome Sales Value by Region (2020-2025)
- 5.1.3 Global Human Microbiome Sales Value by Region (2026-2031)
- 5.1.4 Global Human Microbiome Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Human Microbiome Sales Value, 2020-2031
- 5.2.2 North America Human Microbiome Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Human Microbiome Sales Value, 2020-2031
- 5.3.2 Europe Human Microbiome Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Human Microbiome Sales Value, 2020-2031
- 5.4.2 Asia Pacific Human Microbiome Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Human Microbiome Sales Value, 2020-2031
- 5.5.2 South America Human Microbiome Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Human Microbiome Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Human Microbiome Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Human Microbiome Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Human Microbiome Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Human Microbiome Sales Value, 2020-2031
- 6.3.2 United States Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Human Microbiome Sales Value, 2020-2031
- 6.4.2 Europe Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Human Microbiome Sales Value, 2020-2031
- 6.5.2 China Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Human Microbiome Sales Value, 2020-2031
- 6.6.2 Japan Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Human Microbiome Sales Value, 2020-2031
- 6.7.2 South Korea Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Human Microbiome Sales Value, 2020-2031
- 6.8.2 Southeast Asia Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Human Microbiome Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Human Microbiome Sales Value, 2020-2031
- 6.9.2 India Human Microbiome Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Human Microbiome Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Vedanta
- 7.1.1 Vedanta Profile
- 7.1.2 Vedanta Main Business
- 7.1.3 Vedanta Human Microbiome Products, Services and Solutions
- 7.1.4 Vedanta Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.1.5 Vedanta Recent Developments
- 7.2 Seres Therapeutics
- 7.2.1 Seres Therapeutics Profile
- 7.2.2 Seres Therapeutics Main Business
- 7.2.3 Seres Therapeutics Human Microbiome Products, Services and Solutions
- 7.2.4 Seres Therapeutics Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.2.5 Seres Therapeutics Recent Developments
- 7.3 Second Genome
- 7.3.1 Second Genome Profile
- 7.3.2 Second Genome Main Business
- 7.3.3 Second Genome Human Microbiome Products, Services and Solutions
- 7.3.4 Second Genome Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.3.5 Second Genome Recent Developments
- 7.4 Rebiotix
- 7.4.1 Rebiotix Profile
- 7.4.2 Rebiotix Main Business
- 7.4.3 Rebiotix Human Microbiome Products, Services and Solutions
- 7.4.4 Rebiotix Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.4.5 Rebiotix Recent Developments
- 7.5 ActoGeniX
- 7.5.1 ActoGeniX Profile
- 7.5.2 ActoGeniX Main Business
- 7.5.3 ActoGeniX Human Microbiome Products, Services and Solutions
- 7.5.4 ActoGeniX Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.5.5 ActoGeniX Recent Developments
- 7.6 Enterome BioScience
- 7.6.1 Enterome BioScience Profile
- 7.6.2 Enterome BioScience Main Business
- 7.6.3 Enterome BioScience Human Microbiome Products, Services and Solutions
- 7.6.4 Enterome BioScience Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.6.5 Enterome BioScience Recent Developments
- 7.7 AvidBiotics
- 7.7.1 AvidBiotics Profile
- 7.7.2 AvidBiotics Main Business
- 7.7.3 AvidBiotics Human Microbiome Products, Services and Solutions
- 7.7.4 AvidBiotics Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.7.5 AvidBiotics Recent Developments
- 7.8 4D Pharma Research Ltd
- 7.8.1 4D Pharma Research Ltd Profile
- 7.8.2 4D Pharma Research Ltd Main Business
- 7.8.3 4D Pharma Research Ltd Human Microbiome Products, Services and Solutions
- 7.8.4 4D Pharma Research Ltd Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.8.5 4D Pharma Research Ltd Recent Developments
- 7.9 Enterologics
- 7.9.1 Enterologics Profile
- 7.9.2 Enterologics Main Business
- 7.9.3 Enterologics Human Microbiome Products, Services and Solutions
- 7.9.4 Enterologics Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.9.5 Enterologics Recent Developments
- 7.10 Metabogen
- 7.10.1 Metabogen Profile
- 7.10.2 Metabogen Main Business
- 7.10.3 Metabogen Human Microbiome Products, Services and Solutions
- 7.10.4 Metabogen Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.10.5 Metabogen Recent Developments
- 7.11 Metabiomics
- 7.11.1 Metabiomics Profile
- 7.11.2 Metabiomics Main Business
- 7.11.3 Metabiomics Human Microbiome Products, Services and Solutions
- 7.11.4 Metabiomics Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.11.5 Metabiomics Recent Developments
- 7.12 Ritter Pharmaceuticals
- 7.12.1 Ritter Pharmaceuticals Profile
- 7.12.2 Ritter Pharmaceuticals Main Business
- 7.12.3 Ritter Pharmaceuticals Human Microbiome Products, Services and Solutions
- 7.12.4 Ritter Pharmaceuticals Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.12.5 Ritter Pharmaceuticals Recent Developments
- 7.13 Osel
- 7.13.1 Osel Profile
- 7.13.2 Osel Main Business
- 7.13.3 Osel Human Microbiome Products, Services and Solutions
- 7.13.4 Osel Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.13.5 Osel Recent Developments
- 7.14 Symberix
- 7.14.1 Symberix Profile
- 7.14.2 Symberix Main Business
- 7.14.3 Symberix Human Microbiome Products, Services and Solutions
- 7.14.4 Symberix Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.14.5 Symberix Recent Developments
- 7.15 Miomics
- 7.15.1 Miomics Profile
- 7.15.2 Miomics Main Business
- 7.15.3 Miomics Human Microbiome Products, Services and Solutions
- 7.15.4 Miomics Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.15.5 Miomics Recent Developments
- 7.16 Symbiotix Biotherapies
- 7.16.1 Symbiotix Biotherapies Profile
- 7.16.2 Symbiotix Biotherapies Main Business
- 7.16.3 Symbiotix Biotherapies Human Microbiome Products, Services and Solutions
- 7.16.4 Symbiotix Biotherapies Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.16.5 Symbiotix Biotherapies Recent Developments
- 7.17 MicroBiome Therapeutics LLC
- 7.17.1 MicroBiome Therapeutics LLC Profile
- 7.17.2 MicroBiome Therapeutics LLC Main Business
- 7.17.3 MicroBiome Therapeutics LLC Human Microbiome Products, Services and Solutions
- 7.17.4 MicroBiome Therapeutics LLC Human Microbiome Revenue (US$ Million) & (2020-2025)
- 7.17.5 MicroBiome Therapeutics LLC Recent Developments
8 Industry Chain Analysis
- 8.1 Human Microbiome Industrial Chain
- 8.2 Human Microbiome Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Human Microbiome Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Human Microbiome Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Human Microbiome Market Trends
- Table 2. Human Microbiome Market Drivers & Opportunity
- Table 3. Human Microbiome Market Challenges
- Table 4. Human Microbiome Market Restraints
- Table 5. Global Human Microbiome Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Human Microbiome Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Human Microbiome Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Human Microbiome Product Type
- Table 9. Key Companies Time to Begin Mass Production of Human Microbiome
- Table 10. Global Human Microbiome Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Microbiome as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Human Microbiome Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Human Microbiome Sales Value by Type (2020-2025) & (US$ Million)
- Table 15. Global Human Microbiome Sales Value by Type (2026-2031) & (US$ Million)
- Table 16. Global Human Microbiome Sales Market Share in Value by Type (2020-2025)
- Table 17. Global Human Microbiome Sales Market Share in Value by Type (2026-2031)
- Table 18. Global Human Microbiome Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Human Microbiome Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Human Microbiome Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Human Microbiome Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Human Microbiome Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Human Microbiome Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Human Microbiome Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Human Microbiome Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Human Microbiome Sales Value by Region (2020-2025) & (%)
- Table 27. Global Human Microbiome Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Human Microbiome Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Human Microbiome Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Human Microbiome Sales Value, (2026-2031) & (US$ Million)
- Table 31. Vedanta Basic Information List
- Table 32. Vedanta Description and Business Overview
- Table 33. Vedanta Human Microbiome Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Human Microbiome Business of Vedanta (2020-2025)
- Table 35. Vedanta Recent Developments
- Table 36. Seres Therapeutics Basic Information List
- Table 37. Seres Therapeutics Description and Business Overview
- Table 38. Seres Therapeutics Human Microbiome Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Human Microbiome Business of Seres Therapeutics (2020-2025)
- Table 40. Seres Therapeutics Recent Developments
- Table 41. Second Genome Basic Information List
- Table 42. Second Genome Description and Business Overview
- Table 43. Second Genome Human Microbiome Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Human Microbiome Business of Second Genome (2020-2025)
- Table 45. Second Genome Recent Developments
- Table 46. Rebiotix Basic Information List
- Table 47. Rebiotix Description and Business Overview
- Table 48. Rebiotix Human Microbiome Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Human Microbiome Business of Rebiotix (2020-2025)
- Table 50. Rebiotix Recent Developments
- Table 51. ActoGeniX Basic Information List
- Table 52. ActoGeniX Description and Business Overview
- Table 53. ActoGeniX Human Microbiome Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Human Microbiome Business of ActoGeniX (2020-2025)
- Table 55. ActoGeniX Recent Developments
- Table 56. Enterome BioScience Basic Information List
- Table 57. Enterome BioScience Description and Business Overview
- Table 58. Enterome BioScience Human Microbiome Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Human Microbiome Business of Enterome BioScience (2020-2025)
- Table 60. Enterome BioScience Recent Developments
- Table 61. AvidBiotics Basic Information List
- Table 62. AvidBiotics Description and Business Overview
- Table 63. AvidBiotics Human Microbiome Products, Services and Solutions
- Table 64. Revenue (US$ Million) in Human Microbiome Business of AvidBiotics (2020-2025)
- Table 65. AvidBiotics Recent Developments
- Table 66. 4D Pharma Research Ltd Basic Information List
- Table 67. 4D Pharma Research Ltd Description and Business Overview
- Table 68. 4D Pharma Research Ltd Human Microbiome Products, Services and Solutions
- Table 69. Revenue (US$ Million) in Human Microbiome Business of 4D Pharma Research Ltd (2020-2025)
- Table 70. 4D Pharma Research Ltd Recent Developments
- Table 71. Enterologics Basic Information List
- Table 72. Enterologics Description and Business Overview
- Table 73. Enterologics Human Microbiome Products, Services and Solutions
- Table 74. Revenue (US$ Million) in Human Microbiome Business of Enterologics (2020-2025)
- Table 75. Enterologics Recent Developments
- Table 76. Metabogen Basic Information List
- Table 77. Metabogen Description and Business Overview
- Table 78. Metabogen Human Microbiome Products, Services and Solutions
- Table 79. Revenue (US$ Million) in Human Microbiome Business of Metabogen (2020-2025)
- Table 80. Metabogen Recent Developments
- Table 81. Metabiomics Basic Information List
- Table 82. Metabiomics Description and Business Overview
- Table 83. Metabiomics Human Microbiome Products, Services and Solutions
- Table 84. Revenue (US$ Million) in Human Microbiome Business of Metabiomics (2020-2025)
- Table 85. Metabiomics Recent Developments
- Table 86. Ritter Pharmaceuticals Basic Information List
- Table 87. Ritter Pharmaceuticals Description and Business Overview
- Table 88. Ritter Pharmaceuticals Human Microbiome Products, Services and Solutions
- Table 89. Revenue (US$ Million) in Human Microbiome Business of Ritter Pharmaceuticals (2020-2025)
- Table 90. Ritter Pharmaceuticals Recent Developments
- Table 91. Osel Basic Information List
- Table 92. Osel Description and Business Overview
- Table 93. Osel Human Microbiome Products, Services and Solutions
- Table 94. Revenue (US$ Million) in Human Microbiome Business of Osel (2020-2025)
- Table 95. Osel Recent Developments
- Table 96. Symberix Basic Information List
- Table 97. Symberix Description and Business Overview
- Table 98. Symberix Human Microbiome Products, Services and Solutions
- Table 99. Revenue (US$ Million) in Human Microbiome Business of Symberix (2020-2025)
- Table 100. Symberix Recent Developments
- Table 101. Miomics Basic Information List
- Table 102. Miomics Description and Business Overview
- Table 103. Miomics Human Microbiome Products, Services and Solutions
- Table 104. Revenue (US$ Million) in Human Microbiome Business of Miomics (2020-2025)
- Table 105. Miomics Recent Developments
- Table 106. Symbiotix Biotherapies Basic Information List
- Table 107. Symbiotix Biotherapies Description and Business Overview
- Table 108. Symbiotix Biotherapies Human Microbiome Products, Services and Solutions
- Table 109. Revenue (US$ Million) in Human Microbiome Business of Symbiotix Biotherapies (2020-2025)
- Table 110. Symbiotix Biotherapies Recent Developments
- Table 111. MicroBiome Therapeutics LLC Basic Information List
- Table 112. MicroBiome Therapeutics LLC Description and Business Overview
- Table 113. MicroBiome Therapeutics LLC Human Microbiome Products, Services and Solutions
- Table 114. Revenue (US$ Million) in Human Microbiome Business of MicroBiome Therapeutics LLC (2020-2025)
- Table 115. MicroBiome Therapeutics LLC Recent Developments
- Table 116. Key Raw Materials Lists
- Table 117. Raw Materials Key Suppliers Lists
- Table 118. Human Microbiome Downstream Customers
- Table 119. Human Microbiome Distributors List
- Table 120. Research Programs/Design for This Report
- Table 121. Key Data Information from Secondary Sources
- Table 122. Key Data Information from Primary Sources
List of Figures
- Figure 1. Human Microbiome Product Picture
- Figure 2. Global Human Microbiome Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Human Microbiome Sales Value (2020-2031) & (US$ Million)
- Figure 4. Human Microbiome Report Years Considered
- Figure 5. Global Human Microbiome Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Human Microbiome Revenue in 2024
- Figure 7. Human Microbiome Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. Gastrointestinal Tract Human Micobiome Picture
- Figure 9. Urogenital Tract Human Micobiome Picture
- Figure 10. Others Picture
- Figure 11. Global Human Microbiome Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 12. Global Human Microbiome Sales Value Market Share by Type, 2024 & 2031
- Figure 13. Product Picture of Treatment
- Figure 14. Product Picture of Diagnosis
- Figure 15. Global Human Microbiome Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 16. Global Human Microbiome Sales Value Market Share by Application, 2024 & 2031
- Figure 17. North America Human Microbiome Sales Value (2020-2031) & (US$ Million)
- Figure 18. North America Human Microbiome Sales Value by Country (%), 2024 VS 2031
- Figure 19. Europe Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 20. Europe Human Microbiome Sales Value by Country (%), 2024 VS 2031
- Figure 21. Asia Pacific Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 22. Asia Pacific Human Microbiome Sales Value by Region (%), 2024 VS 2031
- Figure 23. South America Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 24. South America Human Microbiome Sales Value by Country (%), 2024 VS 2031
- Figure 25. Middle East & Africa Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 26. Middle East & Africa Human Microbiome Sales Value by Country (%), 2024 VS 2031
- Figure 27. Key Countries/Regions Human Microbiome Sales Value (%), (2020-2031)
- Figure 28. United States Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 29. United States Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 30. United States Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 31. Europe Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 32. Europe Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 33. Europe Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 34. China Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 35. China Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 36. China Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 37. Japan Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 38. Japan Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 39. Japan Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 40. South Korea Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 41. South Korea Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 42. South Korea Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 43. Southeast Asia Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 44. Southeast Asia Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 45. Southeast Asia Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 46. India Human Microbiome Sales Value, (2020-2031) & (US$ Million)
- Figure 47. India Human Microbiome Sales Value by Type (%), 2024 VS 2031
- Figure 48. India Human Microbiome Sales Value by Application (%), 2024 VS 2031
- Figure 49. Human Microbiome Industrial Chain
- Figure 50. Human Microbiome Manufacturing Cost Structure
- Figure 51. Channels of Distribution (Direct Sales, and Distribution)
- Figure 52. Bottom-up and Top-down Approaches for This Report
- Figure 53. Data Triangulation
- Figure 54. Key Executives Interviewed
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.